PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30715829-15	2016	There Is little evidence that ipratropium, an inhaled short-acting anti-muscarinic bronchodilator, improves COPD symptoms.	Ipratropium	30-41	COPD	Homo sapiens	108-112	
8549206-0	1996	Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.	Ipratropium	69-88	COPD	Homo sapiens	115-119	
27418820-0	2016	Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.	Ipratropium	23-42	COPD	Homo sapiens	141-145	
15500180-4	2004	Anticholinergic bronchodilators, such as ipratropium bromide and especially tiotropium, are first-line anticholinergic agents that can be used alone or in combination with long-acting or short-acting beta2-agonists to achieve these primary goals of COPD treatment.	Ipratropium	41-60	COPD	Homo sapiens	249-253	
22409290-12	2012	The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies.	Ipratropium	61-72	COPD	Homo sapiens	124-128	
21311689-5	2010	RESULTS: With FSC as the reference, risk for a COPD-related hospitalization and/or emergency department visit was significantly higher for ipratropium (hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.50-1.79) and tiotropium (HR 1.29, CI 1.17-1.41).	Ipratropium	139-150	COPD	Homo sapiens	47-51	
21311689-6	2010	Mean adjusted 12-month COPD-related total health care costs were lower for FSC ($2068, standard deviation [SD] $1190) than for ipratropium ($2841, SD $1858) and tiotropium ($2408, SD $1511, both P <0.05).	Ipratropium	127-138	COPD	Homo sapiens	23-27	
15219176-0	2004	A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.	Ipratropium	66-85	COPD	Homo sapiens	117-121	
15219176-1	2004	BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD.	Ipratropium	109-128	COPD	Homo sapiens	188-192	
8549208-0	1996	Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.	Ipratropium	69-88	COPD	Homo sapiens	115-119	
8658369-3	1996	The aim of the present study was to determine the dose of ipratropium bromide aerosol that improves exercise performance using progressive cycle ergometry in patients with stable COPD.	Ipratropium	58-77	COPD	Homo sapiens	179-183	
8658369-12	1996	CONCLUSIONS: A dose of at least four times the standard dose of ipratropium bromide from an MDI with a spacer device was necessary to improve maximal cycle exercise capacity in patients with stable COPD.	Ipratropium	64-83	COPD	Homo sapiens	198-202	
2145136-0	1990	A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD.	Ipratropium	31-50	COPD	Homo sapiens	104-108	
2145136-13	1990	We concluded that for acute exacerbations of COPD, both ipratropium and metaproterenol are effective medications when administered via an MDI attached to a device (Inspirease).	Ipratropium	56-67	COPD	Homo sapiens	45-49